Preclinical study supports a therapeutic role for the immunovascular antibody PC-mAb to preserve cardiac function following heart attack

Stockholm April 23, 2018 Scientists report a study of the effect on cardiac remodeling and function, following treatment with the fully human antibody PC-mAb from Athera, at the 5th congress of Frontiers in Cardiovascular Biology (FCVB). The congress was organized in Vienna by the European Cardiovascular Society (ESC). The group of scientists, from Leiden University Medical Center and the biotech company Athera, concluded that treatment with PC-mAb attenuates the post-ischemic inflammatory response, leading to reduced adverse cardiac remodeling and to preserved cardiac function in this study.

The clinical stage antibody PC-mAb is designed to mimic the anti-inflammatory role of endogenous antibodies against oxidized phospholipid, phosphoryl choline (PC), and act to alleviate the immune response to vascular inflammation challenges and thereby reduce the risk for complications. Heart attack (Myocardial infarction) is preceded by atherosclerosis in the vessels of the heart. During a myocardial infarction there is restricted blood flow (ischemia) in the infarcted areas of the heart. Even if a successful intervention to restore blood flow is performed, the damage may lead to a post-ischemic inflammatory process and related complications, including heart failure. This study supports that PC-mAb may have a therapeutic role to reduce the risk for heart failure complications in myocardial infarction patients.

For more information, contact: Carina Schmidt, CEO, Athera Biotechnologies AB
Phone: +46 (0)76 1938 190, email: c.schmidt@athera.se